AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Justin J. Noznesky sold 1,500 shares of AtriCure stock in a transaction on Monday, April 1st. The shares were sold at an average price of $30.39, for a total transaction of $45,585.00. Following the completion of the sale, the insider now directly owns 72,784 shares in the company, valued at approximately $2,211,905.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
AtriCure Trading Down 2.7 %
Shares of ATRC opened at $26.48 on Thursday. AtriCure, Inc. has a 52-week low of $26.15 and a 52-week high of $59.61. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15. The firm's fifty day moving average is $32.88 and its two-hundred day moving average is $35.72. The stock has a market cap of $1.28 billion, a PE ratio of -40.12 and a beta of 1.38.
AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $103.68 million. During the same quarter in the previous year, the firm earned ($0.09) EPS. The company's quarterly revenue was up 21.0% compared to the same quarter last year. Research analysts forecast that AtriCure, Inc. will post -0.71 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
Several equities research analysts have issued reports on the stock. StockNews.com cut shares of AtriCure from a "hold" rating to a "sell" rating in a research note on Wednesday, March 27th. Needham & Company LLC lifted their target price on shares of AtriCure from $44.00 to $46.00 and gave the stock a "buy" rating in a research note on Friday, February 16th. UBS Group lifted their target price on shares of AtriCure from $57.00 to $58.00 and gave the stock a "buy" rating in a research note on Friday, February 16th. Finally, Stifel Nicolaus lowered their target price on shares of AtriCure from $50.00 to $42.00 and set a "buy" rating on the stock in a research note on Friday, February 16th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $55.57.
View Our Latest Report on AtriCure
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ATRC. RiverPark Advisors LLC purchased a new position in shares of AtriCure during the 3rd quarter worth $27,000. Virtus Fund Advisers LLC purchased a new position in shares of AtriCure during the 4th quarter worth $27,000. Arcadia Investment Management Corp MI purchased a new position in shares of AtriCure during the 3rd quarter worth $28,000. KBC Group NV purchased a new position in shares of AtriCure during the 4th quarter worth $41,000. Finally, Almanack Investment Partners LLC. purchased a new position in shares of AtriCure during the 3rd quarter worth $43,000. Hedge funds and other institutional investors own 99.11% of the company's stock.
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
